Clinical Trial

A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-blind, placebo-controlled, randomized phase 2 study to evaluate the efficacy and safety of CBL-514 injections in participants with Dercum's Disease lipomas.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-03-04; most recent amendment 2026-04-09.
Status change: Recruiting → Active, Not Recruiting 2026-04-09
Status change: Not Yet Recruiting → Recruiting 2024-10-28
Trial Details
NCT Number NCT06303570
Lead Sponsor Caliway Biopharmaceuticals Co., Ltd.
Conditions Dercum's Disease
Enrollment 19 participants
Start Date 2024-11-27
Primary Completion 2026-03-23 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-14